BioLife Advances Oral Peptide Delivery Platform Ahead of London Life Sciences Week
Key Points
- BioLife will present its oral peptide delivery technology and IP developments at London Life Sciences Week.
- Its dissolvable effervescent tablet forms a buffered solution to protect peptides in the GI tract, with preclinical systemic exposure to semaglutide shown.
- The platform is backed by granted US and French patents, with US protection through 2042 covering several GLP-1 agonists.
BioLife Products Limited plans to present its oral peptide delivery technology and latest intellectual property developments at London Life Sciences Week, as the company looks to advance an alternative approach to administering peptide-based medicines.
BioLife’s platform is designed to address one of the key obstacles to oral peptide administration: protecting sensitive molecules from degradation in the gastrointestinal tract while enabling their absorption into systemic circulation. The approach centers on a dissolvable effervescent tablet that forms a buffered solution intended to help protect peptide therapeutics as they move through the digestive system. Its development draws on more than 35 years of pharmaceutical effervescence expertise and approximately 20 years of oral peptide research conducted by company founder and inventor Dr. Farid Bennis.
Preclinical studies have shown measurable systemic exposure to semaglutide following oral administration, which the company describes as in vivo proof of concept. BioLife is also drawing on earlier human clinical research involving oral insulin formulations as it evaluates the platform’s potential for other peptide medicines. Additional research and validation will be required to establish its broader applicability.
The platform is backed by granted patents in the United States and France, with further international patent filings underway. According to BioLife, its U.S. patent includes claims covering several GLP-1 receptor agonists, among them semaglutide, liraglutide, dulaglutide, albiglutide, exenatide and lixisenatide. The patent protection extends through 2042.
BioLife’s development program has included human clinical research involving oral insulin formulations, as well as work with Charles River Laboratories, SGS, Eurofins/Amatsi and Cephac. The technology remains under development and is not approved for the treatment of any disease.
For more information, visit https://biolife.bio/
Total Page Views: 16
